Misplaced Pages

Revision as of 10:00, 31 October 2011

This article needs attention from an expert on the subject. Please add a reason or a talk parameter to this template to explain the issue with the article. When placing this tag, consider associating this request with a WikiProject. (March 2010)

This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Insulin lispro" – news · newspapers · books · scholar · JSTOR (March 2010) (Learn how and when to remove this message)

Insulin lispro (marketed by Eli Lilly and Company as "Humalog") is a fast acting insulin analogue; it was the first insulin analogue, and is similar to insulin aspart.

Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.

Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin for good glycemic control.

References

1. "Insulin Lispro: A Fast-Acting Insulin Analog". Retrieved 2007-06-08.

External links

• FDA Warning Letter to Lilly re: instability of Humalog Crystals-February 22, 2010

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Eli Lilly and Company
• Insulin therapies
• Diabetes
• Human proteins
• Recombinant proteins
• Peptide hormones
• Gastrointestinal system drug stubs